EMEND IV 150 MG

País: Israel

Idioma: inglés

Fuente: Ministry of Health

Ingredientes activos:

FOSAPREPITANT AS FOSAPREPITANT DIMEGLUMINE 150 MG

Disponible desde:

MERCK SHARP & DOHME ISRAEL LTD

Código ATC:

A04AD12

formulario farmacéutico:

POWDER FOR SOLUTION FOR INFUSION

Vía de administración:

I.V

Fabricado por:

MERCK SHARP & DOHME B.V, HOLLAND

Grupo terapéutico:

APREPITANT

indicaciones terapéuticas:

Emend IV 150mg in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose Cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

Fecha de autorización:

2011-11-01